JPRN-UMIN000014096已完成2 期
A phase II study of S-1 (14days-administrarion followed by 7days-rest ) for Metastatic Breast Cancer - A phase II study of S-1 (14days-administrarion followed by 7days-rest) for Metastatic Breast Cancer
Tokyo Women's Medical University0 个研究点目标入组 25 人开始时间: 2014年6月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(1)HER2 positive (IHC:3+ or FISH +) (2)History of non-breast malignancies within the 5 years prior to study entry (3)Symptomatic brain metastasis (4)Diffuse liver meta, or carcinomatous lymphangitis. (5)In addition, the case that a investigator judged to be inadequate
研究者
相似试验
已完成
2 期
Phase II study of 3-weeks cycle of S-1 as first-line for advanced pancreatic cancer (PACS-3)advanced pancreatic cancerJPRN-UMIN000011179Gifu University Hospital70
未知
2 期
Phase II Study of S-1 plus LV (1 week on and 1 week off) as First-line Treatment for Patients with metastatic colorectal cancer.Colorectal CancerJPRN-jRCT2080220727Taiho Pharmaceutical Co., Ltd.
已完成
2 期
Phase II study of alternate-day treatment with S-1 as adjuvant chemotherapy for patients with lung cancer.lung cancerJPRN-UMIN000011370Chiba University Graduate School of Medicine25
已完成
2 期
A Multicenter phase II study of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanved non-squamous non-small cell lung cancerJPRN-UMIN000007386Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine28
招募中
2 期
Randomized phase II study with S-1 (4week treatment and 2week rest) or S-1 (Alternate day administration) adjuvant chemotherapy for patients with pancreatic cancerResected pancreatic cancerJPRN-UMIN000010922HORE70